Hikma Pharmaceuticals PLC (LON:HIK)
London
· Delayed Price · Currency is GBP · Price in GBX 1,191.00
-18.00 (-1.49%)
At close: Mar 9, 2026
Hikma Pharmaceuticals Ratios and Metrics
Market cap in millions GBP. Fiscal year is January - December.
Millions GBP. Fiscal year is Jan - Dec.
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 6, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Market Capitalization | 2,652 | 3,433 | 4,419 | 3,955 | 3,418 | 5,136 | Upgrade
|
| Market Cap Growth | -48.09% | -22.33% | 11.74% | 15.72% | -33.45% | -11.50% | Upgrade
|
| Enterprise Value | 3,692 | 4,407 | 5,234 | 4,766 | 4,383 | 5,569 | Upgrade
|
| Last Close Price | 12.09 | 15.50 | 19.29 | 16.78 | 14.17 | 19.78 | Upgrade
|
| PE Ratio | 8.99 | 11.49 | 15.41 | 26.52 | 21.91 | 16.52 | Upgrade
|
| Forward PE | 6.97 | 8.95 | 10.90 | 10.80 | 9.65 | 14.20 | Upgrade
|
| PS Ratio | 1.07 | 1.38 | 1.77 | 1.75 | 1.64 | 2.72 | Upgrade
|
| PB Ratio | 1.37 | 1.77 | 2.38 | 2.28 | 1.92 | 2.82 | Upgrade
|
| P/TBV Ratio | 2.51 | 3.25 | 4.79 | 4.59 | 4.07 | 4.46 | Upgrade
|
| P/FCF Ratio | 14.93 | 19.33 | 13.87 | 11.48 | 10.51 | 14.11 | Upgrade
|
| P/OCF Ratio | 8.19 | 10.60 | 9.81 | 8.29 | 7.77 | 10.90 | Upgrade
|
| PEG Ratio | 1.11 | 1.24 | 1.66 | 1.55 | 2.10 | 1.49 | Upgrade
|
| EV/Sales Ratio | 1.48 | 1.77 | 2.10 | 2.11 | 2.10 | 2.95 | Upgrade
|
| EV/EBITDA Ratio | 5.99 | 7.24 | 8.33 | 7.62 | 7.88 | 10.50 | Upgrade
|
| EV/EBIT Ratio | 7.95 | 9.49 | 10.78 | 9.71 | 10.61 | 13.44 | Upgrade
|
| EV/FCF Ratio | 20.79 | 24.82 | 16.42 | 13.83 | 13.47 | 15.30 | Upgrade
|
| Debt / Equity Ratio | 0.62 | 0.62 | 0.56 | 0.54 | 0.60 | 0.34 | Upgrade
|
| Debt / EBITDA Ratio | 1.93 | 1.93 | 1.64 | 1.46 | 1.88 | 1.16 | Upgrade
|
| Debt / FCF Ratio | 6.71 | 6.71 | 3.27 | 2.71 | 3.27 | 1.72 | Upgrade
|
| Net Debt / Equity Ratio | 0.53 | 0.53 | 0.47 | 0.44 | 0.46 | 0.16 | Upgrade
|
| Net Debt / EBITDA Ratio | 1.69 | 1.69 | 1.39 | 1.21 | 1.48 | 0.55 | Upgrade
|
| Net Debt / FCF Ratio | 5.80 | 5.80 | 2.74 | 2.19 | 2.53 | 0.80 | Upgrade
|
| Asset Turnover | 0.62 | 0.62 | 0.64 | 0.63 | 0.57 | 0.60 | Upgrade
|
| Inventory Turnover | 1.82 | 1.82 | 1.82 | 1.76 | 1.70 | 1.73 | Upgrade
|
| Quick Ratio | 0.89 | 0.89 | 0.60 | 0.82 | 1.05 | 1.31 | Upgrade
|
| Current Ratio | 1.82 | 1.82 | 1.14 | 1.57 | 1.86 | 2.06 | Upgrade
|
| Return on Equity (ROE) | 16.52% | 16.52% | 15.98% | 8.81% | 8.28% | 18.20% | Upgrade
|
| Return on Assets (ROA) | 7.23% | 7.23% | 7.75% | 8.54% | 7.04% | 8.24% | Upgrade
|
| Return on Invested Capital (ROIC) | 12.28% | 13.23% | 14.69% | 13.54% | 13.60% | 15.48% | Upgrade
|
| Return on Capital Employed (ROCE) | 14.80% | 14.80% | 19.30% | 18.70% | 14.70% | 16.70% | Upgrade
|
| Earnings Yield | 11.26% | 8.70% | 6.49% | 3.77% | 4.57% | 6.05% | Upgrade
|
| FCF Yield | 6.70% | 5.17% | 7.21% | 8.71% | 9.52% | 7.09% | Upgrade
|
| Dividend Yield | 5.19% | 4.03% | 3.31% | 3.37% | 3.28% | 2.02% | Upgrade
|
| Payout Ratio | 46.02% | 46.02% | 48.75% | 72.10% | 66.49% | 28.50% | Upgrade
|
| Buyback Yield / Dilution | 0.36% | 0.36% | -0.51% | 1.13% | 3.47% | 2.10% | Upgrade
|
| Total Shareholder Return | 5.55% | 4.39% | 2.81% | 4.50% | 6.75% | 4.12% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.